PetVivo (PETV) 10-Q/A 18 Aug 21 2022 Q1 Quarterly report (amended) Financial data

Cover

Cover - shares	3 Months Ended
	Jun. 30, 2021	Aug. 13, 2021
Document Information [Line Items]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 (the “Amendment”) to the Quarterly Report on Form 10-Q of PetVivo Holdings, Inc. (the “Company”) for the quarter ended June 30, 2021, originally filed with the Securities and Exchange Commission on August 16, 2021 (the “Original Form 10-Q”) is being filed to complete the filing by tagging the Original Form 10-Q for inline XBRL which not originally included as a result of technical difficulties.
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--03-31
Entity File Number	000-55167
Entity Registrant Name	PetVivo Holdings Inc.
Entity Central Index Key	0001512922
Entity Tax Identification Number	99-0363559
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5251 Edina Industrial Blvd.
Entity Address, City or Town	Edina
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55439
City Area Code	952
Local Phone Number	405-6216
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,647,711
Common Stock, par value $0.001 [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	PETV
Security Exchange Name	NASDAQ
Warrants to Purchase Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	PETVW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Current Assets
Cash and cash equivalents	$ 143,084	$ 23,578
Accounts receivable
Inventory, net
Prepaid expenses and other assets	102,550	123,575
Total Current Assets	245,634	147,153
Property and Equipment, net	202,168	214,038
Other Assets:
Deferred offering costs	305,353	280,163
Operating lease right-of-use	151,190	157,760
Trademark and patents, net	32,267	27,932
Security deposit	8,201	8,201
Total Other Assets	497,011	474,056
Total Assets	944,813	835,247
Current Liabilities
Accounts payable and accrued expenses	1,149,040	962,885
Convertible notes and accrued interest		235,671
Accrued expenses – related parties	50,898	36,808
Operating lease liability – short term	26,754	26,582
PPP Loan and accrued interest	7,436	39,020
Notes payable and accrued interest - directors	20,300	20,000
Notes payable and accrued interest – related party	48,267	44,554
Note payable and accrued interest	37,860	39,528
Total Current Liabilities	1,340,555	1,405,048
Other Liabilities
Operating lease liability (net of current)	124,436	131,178
Share-settled debt obligation – related party, net of debt discount	196,000	196,000
Total Other Liabilities	320,436	327,178
Total Liabilities	1,660,991	1,732,226
Commitments and Contingencies (see Note 13)
Stockholders’ Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized, issued 0 and 0 shares outstanding at June 30, 2021 and March 31, 2021
Common stock, par value $0.001, 250,000,000 shares authorized, issued 7,093,155 and 6,799,113 shares outstanding at June 30, 2021 and March 31, 2021	7,093	6,799
Additional Paid-In Capital	57,878,784	57,207,648
Accumulated Deficit	(58,602,055)	(58,111,426)
Total Stockholders’ Deficit	(716,178)	(896,979)
Total Liabilities and Stockholders’ Deficit	$ 944,813	$ 835,247

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Mar. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	7,093,155	6,799,113
Common stock, shares outstanding	7,093,155	6,799,113

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 4,145	$ 2,006
Cost of Sales	5,051
Gross Profit	(906)	2,006
Operating Expenses:
Sales and Marketing	49,731	46,682
General and administrative	330,945	397,392
Research and development	136,937
Total Operating Expenses	517,613	444,074
Operating Loss	(518,519)	(442,068)
Other Income (Expense)
Gain on Sale of Asset		482
Forgiveness of PPP loan and accrued interest	31,680
Derivative expense		(342,200)
Interest Expense and other	(3,790)	(30,222)
Total Other Income (Expense)	27,890	(371,940)
Net Loss before taxes	(490,629)	(814,008)
Income Tax Provision
Net Loss	$ (490,629)	$ (814,008)
Net Loss Per Share:
Basic and Diluted	$ (0.07)	$ (0.16)
Weighted Average Common Shares Outstanding:
Basic and Diluted	6,946,353	5,161,101

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock to be Issued [Member]	Total
Beginning balance, value at Mar. 31, 2020	$ 5,728	$ 53,494,748	$ (54,588,645)	$ 52,000	$ (1,036,170)
Beginning balance, shares at Mar. 31, 2020	5,727,965
Common stock and warrants sold	$ 20	51,980		(52,000)
Common stock and warrants sold, shares	20,000
Warrants issued with convertible debt		91,500			91,500
Stock-based compensation	$ 30	183,214			183,244
Stock-based compensation, shares	30,000
Net loss			(814,008)		(814,008)
Ending balance, value at Jun. 30, 2020	$ 5,778	53,821,442	(55,402,653)		(1,575,434)
Ending balance, shares at Jun. 30, 2020	5,777,965
Beginning balance, value at Mar. 31, 2021	$ 6,799	57,207,648	(58,111,426)		(896,979)
Beginning balance, shares at Mar. 31, 2021	6,799,113
Common stock sold	$ 50	343,048			343,098
Common stock sold, shares	49,014
Cash paid to exercise warrants	$ 4	39,996			40,000
Cash paid to exercise warrants, shares	4,500
Stock issued for debt conversion	$ 80	232,578			232,658
Stock issued for debt conversion, shares	80,522
Cashless warrant exercises	$ 160	(160)
Cashless warrant exercises, shares	160,006
Stock-based compensation		55,674			55,674
Net loss			(490,629)		(490,629)
Ending balance, value at Jun. 30, 2021	$ 7,093	$ 57,878,784	$ (58,602,055)		$ (716,178)
Ending balance, shares at Jun. 30, 2021	7,093,155

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss For The Period	$ (490,629)	$ (814,008)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Derivative expense		342,200
Stock-based compensation	55,674	183,244
Depreciation and amortization	13,599	51,805
Amortization of debt discount		19,608
Forgiveness of PPP loan and accrued interest	(31,680)
Intangible impairment		3,606
Gain on sale of asset		(482)
Changes in Operating Assets and Liabilities
(Increase) decrease in prepaid expenses and other assets	21,025	(4,347)
Increase in accounts receivable		(1,000)
Deferred offering costs	(25,190)
Interest accrued on convertible notes payable	192	8,819
Interest accrued on notes payable - related party	4,013	1,387
Interest accrued on notes payable	96	295
Increase (decrease) in accounts payable and accrued expense	182,949	(13,224)
Increase (decrease) in accrued expenses - related party	14,090	(13,234)
Net Cash Used In Operating Activities	(255,861)	(235,331)
CASH FLOWS FROM INVESTING ACTIVITIES
Sale of equipment		482
Purchase of equipment		(41,236)
Increase in patents and trademarks	(6,063)	(5,136)
Net Cash Used in Investing Activities	(6,063)	(45,890)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from common stock sold	343,098	52,000
Proceeds from exercise of warrants	40,000
Proceeds from PPP loan		38,665
Proceeds from convertible notes		322,500
Repayments of convertible notes		(13,962)
Repayments of notes payable	(1,668)
Net Cash Provided by Financing Activities	381,430	399,203
Net Increase in Cash	119,506	117,982
Cash at Beginning of Period	23,578	10,582
Cash at End of Period	143,084	128,564
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	3,889	13,962
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING AND INVESTING ACTIVITIES
Derivative treated as debt discount		352,941
Stock granted for debt conversion	$ 232,658

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	3 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 250,000,000 (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. As of June 30, 2021 and March 31, 2021, the Company did not have any cash balances in excess of the federally insured limits. (H) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of ( 3 5 7 (I) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 (J) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 731,444 1.20 10.00 2.15 The Company has 1,288,937 1.33 17.28 2.27 The Company uses the guidance in Accounting Standards Codification 260 (“ASC 260”) to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At June 30, 2021, the Company has a Share-Settled Debt Obligation to a Related Party of $ 196,000 (K) Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon shipment of our pet care products to our customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. (L) Research and Development The Company expenses research and development costs as incurred. (M) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related parties, notes payable and accrued interest, and notes payable and accrued interest - related party, notes payable – directors and others. The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2021 and March 31, 2021, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no (N) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. (O) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC Topic 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (P) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology. (Q) Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. The Company adopted Topic 842 on April 1, 2019 and resulted in a right of use asset and liability of $ 154,917 All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

INVENTORY

INVENTORY	3 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY As of June 30, 2021 and March 31, 2021, the Company had inventory of $ 41,468 47,068 The inventory components are as follows: SCHEDULE OF INVENTORY June 30, 2021 March 31, 2021 Finished Goods $ 34,123 $ 36,973 Raw Materials 6,273 8,773 Manufacturing Supplies 1,072 1,322 Inventory, Gross 41,468 47,068 Reserve for Obsolete Inventory (41,468 ) (47,068 ) Total Net $ — $ — The Company recognized income of $ 3,289

PREPAID EXPENSES AND DEFERRED O

PREPAID EXPENSES AND DEFERRED OFFERING COSTS	3 Months Ended
	Jun. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND DEFERRED OFFERING COSTS	NOTE 3 – PREPAID EXPENSES AND DEFERRED OFFERING COSTS As of June 30, 2021, the Company had $ 102,550 84,000 10,000 6,000 305,353 As of March 31, 2021, the Company had $ 123,575 78,000 9,000 9,000 280,163

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2021 March 31, 2021 Leasehold improvements $ 198,015 $ 198,015 Production equipment 128,849 128,849 R&D equipment 25,184 25,184 Furniture 10,130 10,130 Total, at cost 362,178 362,178 Accumulated depreciation (160,010 ) (148,140 ) Total Net $ 202,168 $ 214,038 Depreciation expense was $ 11,870 6,489

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS The components of intangible assets, all of which are finite-lived, were as follows: SCHEDULE OF INTANGIBLE ASSETS June 30, 2021 March 31, 2021 Patents $ 3,846,967 $ 3,840,903 Trademarks 26,142 26,142 Total at cost 3,873,109 3,867,045 Accumulated Amortization (3,840,842 ) (3,839,113 ) Total net $ 32,267 $ 27,932 Amortization expense was $ 1,729 45,316 3,606

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES The components of accounts payable and accrued expenses were as follows: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, 2021 March 31, 2021 Accounts payable $ 905,736 $ 741,111 Accrued payroll and related taxes 243,304 221,774 Total $ 1,149,040 $ 962,885

RELATED PARTY NOTES PAYABLE

RELATED PARTY NOTES PAYABLE	3 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY NOTES PAYABLE	NOTE 7 - RELATED PARTY NOTES PAYABLE At June 30, 2021 and March 31, 2021, the Company is obligated for a related party note payable and accrued interest in the total amount of $ 48,267 44,554 June 30, 2022 3,100 24 3,500,000 The Company entered into notes payable with four directors in March 2021 which accrue interest at a rate of 6% 20,300 20,000

NOTES PAYABLE AND CONVERTIBLE N

NOTES PAYABLE AND CONVERTIBLE NOTES	3 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE AND CONVERTIBLE NOTES	NOTE 8 – NOTES PAYABLE AND CONVERTIBLE NOTES In January 2020, the Company entered into a lease amendment for our corporate office facility whereby the lease term was extended through November of 2026 in exchange for a loan of $ 42,500 6% 37,860 39,528 On May 1, 2020, the Company received $ 38,665 39,020 1% May 1, 2022 31,680 7,436 738 At March 31, 2021, the Company was obligated for several convertible notes payable in the total amount of $ 235,671 230,000 5,671 2,658 80,522 2.89 10% 3,093 3,397 At June 30, 2020, the Company is obligated for one convertible note payable held by RedDiamond Partners, LLC (“RDCN”); the Company entered into the RDCN on June 15, 2020, whereby the note is convertible on or after January 15, 2021 and before maturity on March 15, 2021 at a rate of $ .28 352,941 52,941 15% 12.5% 354,779 1,838 557,143 91,500 0 352,941 91,500 2,500 2,500 206,000 333,333 0 19,608 30,000 75,000 31,500 61,500 52,399

SHARE-SETTLED DEBT OBLIGATION _

SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY	3 Months Ended
	Jun. 30, 2021
Share-settled Debt Obligation Related Party
SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY	NOTE 9 – SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY Effective September 1, 2020, the Company entered into two debt settlement agreements with David B. Masters, a director of the Company, pursuant to an Amendment to Promissory Note and a Promissory Note. The Amendment to Promissory Note extends, for up to an additional two years and under the same terms as originally entered into, the original promissory notes which were issued by Gel-Del Technologies, Inc., a wholly owned subsidiary of the Company, to Dr. Masters. Because this Amendment to Promissory Note simply extended the term over which the Company is required to pay back the outstanding balance this change has been treated as a debt modification. The outstanding principal of $ 59,642 6,058 65,700 8% 20% The Amendment to Promissory Note requires monthly payments of $ 3,100 June 30, 2022 The Promissory Note was entered into with an effective date of September 1, 2020 in a principal amount of $ 195,000 David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3% August 31, 2022 4,000 A Settlement and General Release (“ Settlement Agreement On October 15, 2020, the Company entered into a note conversion agreement with David Masters whereby the Company and Mr. Masters both agreed to convert his note payable in the then outstanding balance of $ 193,158 192,500 658 196,000 192,500 3,500 658 3,500 196,000 At June 30, 2021 and March 31, 2021, the Company was obligated for principal and accrued interest in the amounts of $- 0 0 48,267 44,554

DERIVATIVE LIABILITY AND EXPENS

DERIVATIVE LIABILITY AND EXPENSE	3 Months Ended
	Jun. 30, 2021
Derivative Liability And Expense
DERIVATIVE LIABILITY AND EXPENSE	NOTE 10 – DERIVATIVE LIABILITY AND EXPENSE The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operation as other income (expense). Upon conversion or exercise of a derivative instruments, the instrument is marked to fair value at the conversion date then that fair value is recognized as a gain or loss on extinguishment. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020 and June 30, 2020, the issuance and balance sheet dates, respectively: SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS June 15, 2020 June 30, 2020 Stock price on valuation date $ .42 $ .44 Conversion price $ .28 $ .28 Days to maturity 273 258 Weighted-average volatility* 367 % 367 % Risk-free rate .18 % .18 % The initial valuation of $ 526,800 206,000 0 320,800 526,800 0 0 21,400

ACCRUED EXPENSES _ RELATED PART

ACCRUED EXPENSES – RELATED PARTY	3 Months Ended
	Jun. 30, 2021
Accrued Expenses Related Party
ACCRUED EXPENSES – RELATED PARTY	NOTE 11– ACCRUED EXPENSES – RELATED PARTY At June 30, 2021, the Company was obligated to pay $ 50,898 29,855 21,043 At March 31, 2021, the Company was obligated to pay $ 36,808 28,965 7,843

RETIREMENT PLAN

RETIREMENT PLAN	3 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
RETIREMENT PLAN	NOTE 12– RETIREMENT PLAN In February 2021, the Company established a 401(k) retirement plan for its employees in which eligible employees can contribute a percentage of their compensation. The Company may also make discretionary contributions. The Company did not make any contributions to the plan for the three months ended June 30, 2021.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES The Company entered into an eighty-four-month lease for 3,577 2% This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. In January 2020, the Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026 42,500 7,500 2,205 Rent expense for the three months ended June 30, 2021 and 2020 were $ 11,511 13,568 The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of June 30, 2021: SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2021 2022 $ 20,020 2023 27,167 2024 27,710 2025 28,265 2026 28,830 2027 19,474 Total $ 151,466 Less: amount representing interest (276 ) Total $ 151,190 In compliance with ASC 842, the Company recognized, based on the extended lease term to November 2026 and a treasury rate of 0.12% 189,600 6 0.12% SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 151,190 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 151,190 As of June 30, 2021, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 151,190 Total operating lease assets 151,190 Operating lease current liability 26,754 Operating lease other liability 124,436 Total operating lease liabilities $ 151,190 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until and through the lease’s termination in fiscal year 2017-2018, the Company had recorded as of those fiscal years approximately $ 330,000 The Company has employment agreements with the Chief Executive Officer and Chief Financial Officer. As of June 30, 2021 and March 31, 2021, these agreements do not contain severance benefits if terminated without cause.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 14 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company incurred net losses of $ 490,629 255,861 58,602,055 1,094,921 716,178 Management intends to raise additional funds either through a private placement or public offering of its equity securities. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. COVID-19 has had an impact on the global economy, which directly or indirectly may have an impact on our ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

COMMON STOCK AND WARRANTS

COMMON STOCK AND WARRANTS	3 Months Ended
	Jun. 30, 2021
Equity [Abstract]
COMMON STOCK AND WARRANTS	NOTE 15 – COMMON STOCK AND WARRANTS Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), subject to approval by our stockholders at the Regular Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. The number of shares of our common stock available and that may be issued as awards under the 2020 Plan is 1,000,000 July 10, 2030 Employees, consultants and advisors of the Company (or any subsidiary), and non-employee directors of the Company will be eligible to receive awards under the 2020 Plan. In the case of consultants and advisors, however, their services cannot be in connection with the offer and sale of securities in a capital-raising transaction nor directly or indirectly promote or maintain a market for PetVivo securities. The 2020 Plan will be administered by the Compensation Committee of our Board of Directors (the “Committee”), which has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment, any deferral payment, and other terms and conditions of each award. Subject to provisions of the 2020 Plan, the Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Committee also has the authority to interpret and establish rules and regulations for the administration of the 2020 Plan. In addition, the Board of Directors may also exercise the powers of the Committee. The aggregate number of shares of Petvivo common stock available and reserved to be issued under the 2020 Plan is 1,000,000 ● the maximum aggregate number of shares of Common Stock granted as an Award to any Non-Employee Director in any one Plan Year will be 10,000 Awards can be granted for no cash consideration or for any cash and other consideration as determined by the Committee. Awards may provide that upon the grant or exercise thereof, the holder will receive cash, shares of PetVivo common stock, other securities or property, or any combination of these in a single payment, installments or on a deferred basis. The exercise price per share of any stock option and the grant price of any stock appreciation right may not be less than the fair market value of PetVivo common stock on the date of grant. The term of any award cannot be longer than ten years from the date of grant. Awards will be adjusted in the event of a stock dividend or other distribution, recapitalization, forward or reverse stock split, reorganization, merger or other business combination, or similar corporate transaction, in order to prevent dilution or enlargement of the benefits or potential benefits provided under the 2020 Plan. The 2020 Plan permits the following types of awards: stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, other stock-based awards, and dividend equivalents. As of June 30, 2021, the Company has granted 34,300 300 Common Stock For the three months ended June 30, 2021, the Company issued 294,042 i) 80,522 230,000 2,658 2.89 ii) 4,500 4.44 40,000 iii) 36,915 42,188 1.33 iv) 79,767 139,286 1.40 v) 49,014 343,098 7.00 vi) 43,324 56,250 2.22 For the three months ended June 30, 2020, the Company issued 50,000 i) i) 30,000 32,453 ii) 20,000 34,709 34,709 17,291 52,000 Warrants During the three months ended June 30, 2021, no warrants were issued. During the three months ended June 30, 2020, the Company issued warrants to purchase a total of 206,873 i) warrants issued for 10,000 17,291 4.00 3 ii) warrants issued for 38,837 57,717 1.40 1.60 1.52 iii) warrants issued with debt for 158,036 265,500 91,500 1.40 five years These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of between approximately 350 433 ii) risk-free rates identical to the U.S. Treasury 3 5 0.29 1.16 A summary of warrant activity for the year ending March 31, 2021 and three-month period ending June 30, 2021 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Weighted- Warrants Weighted- Outstanding, March 31, 2020 1,234,295 $ 2.12 1,027,092 $ 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (205,946 ) (2.21 ) Cashless warrant exercises (142,313 ) (1.64 ) Expired (45,000 ) (3.78 ) Outstanding, March 31, 2021 1,081,668 2.02 881,982 2.00 Exercised for cash (4,500 ) (8.89 ) Cashless warrant exercises (237,724 ) (1.58 ) Cancelled (108,000 ) (1.80 ) Outstanding, June 30, 2021 731,444 $ 2.15 557,069 $ 2.17 At June 30, 2021, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 419,831 $ 1.35 4.68 397,331 $ 1.35 2.01 4.00 207,938 2.48 3.09 56,063 3.15 4.01 10.00 103,675 4.77 1.32 103,675 4.77 Total 731,444 2.15 3.75 557,069 2.17 For the three months ended June 30, 2021 and 2020, the total stock-based compensation on all instruments was $ 55,674 183,244 104,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 – SUBSEQUENT EVENTS In July of 2021, the Company sold an aggregate of 11,000 7 77,000 On August 13, 2021, the Company sold an aggregate of 2,500,000 4.50 9,800,000 375,000 375,000 125,000 5.625 August 10, 2026

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	3 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 250,000,000
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. As of June 30, 2021 and March 31, 2021, the Company did not have any cash balances in excess of the federally insured limits.
Property & Equipment	(H) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of ( 3 5 7
Patents and Trademarks	(I) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60
Loss Per Share	(J) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 731,444 1.20 10.00 2.15 The Company has 1,288,937 1.33 17.28 2.27 The Company uses the guidance in Accounting Standards Codification 260 (“ASC 260”) to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At June 30, 2021, the Company has a Share-Settled Debt Obligation to a Related Party of $ 196,000
Revenue Recognition	(K) Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon shipment of our pet care products to our customers in an amount that reflects the consideration we expect to receive in exchange for those products or services.
Research and Development	(L) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(M) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related parties, notes payable and accrued interest, and notes payable and accrued interest - related party, notes payable – directors and others. The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2021 and March 31, 2021, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no
Stock-Based Compensation - Non-Employees	(N) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Income Taxes	(O) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC Topic 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(P) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology.
Recent Accounting Pronouncements	(Q) Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. The Company adopted Topic 842 on April 1, 2019 and resulted in a right of use asset and liability of $ 154,917 All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	The inventory components are as follows: SCHEDULE OF INVENTORY June 30, 2021 March 31, 2021 Finished Goods $ 34,123 $ 36,973 Raw Materials 6,273 8,773 Manufacturing Supplies 1,072 1,322 Inventory, Gross 41,468 47,068 Reserve for Obsolete Inventory (41,468 ) (47,068 ) Total Net $ — $ —

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2021 March 31, 2021 Leasehold improvements $ 198,015 $ 198,015 Production equipment 128,849 128,849 R&D equipment 25,184 25,184 Furniture 10,130 10,130 Total, at cost 362,178 362,178 Accumulated depreciation (160,010 ) (148,140 ) Total Net $ 202,168 $ 214,038

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The components of intangible assets, all of which are finite-lived, were as follows: SCHEDULE OF INTANGIBLE ASSETS June 30, 2021 March 31, 2021 Patents $ 3,846,967 $ 3,840,903 Trademarks 26,142 26,142 Total at cost 3,873,109 3,867,045 Accumulated Amortization (3,840,842 ) (3,839,113 ) Total net $ 32,267 $ 27,932

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES	The components of accounts payable and accrued expenses were as follows: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, 2021 March 31, 2021 Accounts payable $ 905,736 $ 741,111 Accrued payroll and related taxes 243,304 221,774 Total $ 1,149,040 $ 962,885

DERIVATIVE LIABILITY AND EXPE_2

DERIVATIVE LIABILITY AND EXPENSE (Tables)	3 Months Ended
	Jun. 30, 2021
Derivative Liability And Expense
SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS	The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020 and June 30, 2020, the issuance and balance sheet dates, respectively: SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS June 15, 2020 June 30, 2020 Stock price on valuation date $ .42 $ .44 Conversion price $ .28 $ .28 Days to maturity 273 258 Weighted-average volatility* 367 % 367 % Risk-free rate .18 % .18 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of June 30, 2021: SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2021 2022 $ 20,020 2023 27,167 2024 27,710 2025 28,265 2026 28,830 2027 19,474 Total $ 151,466 Less: amount representing interest (276 ) Total $ 151,190
SCHEDULE OF BASE RENT LEASE PAYMENTS	SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 151,190 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 151,190
SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES	As of June 30, 2021, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 151,190 Total operating lease assets 151,190 Operating lease current liability 26,754 Operating lease other liability 124,436 Total operating lease liabilities $ 151,190

COMMON STOCK AND WARRANTS (Tabl

COMMON STOCK AND WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2021
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	A summary of warrant activity for the year ending March 31, 2021 and three-month period ending June 30, 2021 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Weighted- Warrants Weighted- Outstanding, March 31, 2020 1,234,295 $ 2.12 1,027,092 $ 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (205,946 ) (2.21 ) Cashless warrant exercises (142,313 ) (1.64 ) Expired (45,000 ) (3.78 ) Outstanding, March 31, 2021 1,081,668 2.02 881,982 2.00 Exercised for cash (4,500 ) (8.89 ) Cashless warrant exercises (237,724 ) (1.58 ) Cancelled (108,000 ) (1.80 ) Outstanding, June 30, 2021 731,444 $ 2.15 557,069 $ 2.17
SCHEDULE OF RANGE OF WARRANT PRICES	SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 419,831 $ 1.35 4.68 397,331 $ 1.35 2.01 4.00 207,938 2.48 3.09 56,063 3.15 4.01 10.00 103,675 4.77 1.32 103,675 4.77 Total 731,444 2.15 3.75 557,069 2.17

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Dec. 29, 2020	Jan. 31, 2020	Apr. 02, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reverse stock split, description	the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all periods presented.
Common stock, shares authorized		250,000,000		250,000,000	225,000,000
Cash equivalents		$ 0		$ 0
Share-settled debt obligation with a related party		196,000
Assets and liabilities measured at fair value		$ 0		0
Income tax likelihood percentage		greater than 50 percent
Right of use-asset		$ 151,190		$ 157,760		$ 189,600
Operating lease liability		$ 151,190				$ 189,600
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right of use-asset							$ 154,917
Operating lease liability							$ 154,917
Warrant [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrants outstanding		731,444	1,288,937
Weighted average, exercise price		$ 2.15	$ 2.27
Warrant [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrant exercise price		1.20	1.33
Warrant [Member] | Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrant exercise price		$ 10	$ 17.28
Patents and Trademarks [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful life of intangible asset		60 months
Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful life of assets		3 years
Automobiles [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful life of assets		5 years
Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful life of assets		7 years

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Inventory Disclosure [Abstract]
Finished Goods	$ 34,123	$ 36,973
Raw Materials	6,273	8,773
Manufacturing Supplies	1,072	1,322
Inventory, Gross	41,468	47,068
Reserve for Obsolete Inventory	(41,468)	(47,068)
Total Net

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory, Gross	$ 47,068	$ 41,468
Income recognized, change in reserve of obsolete inventory	$ 3,289

PREPAID EXPENSES AND DEFERRED_2

PREPAID EXPENSES AND DEFERRED OFFERING COSTS (Details Narrative) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Prepaid expenses and other assets	$ 102,550	$ 123,575
Deferred offering costs	305,353	280,163
Advertising and Marketing Services [Member]
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Prepaid expenses and other assets	84,000	78,000
Insurance Costs [Member]
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Prepaid expenses and other assets	10,000	9,000
Rent [Member]
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Prepaid expenses and other assets	$ 6,000
License [Member]
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Prepaid expenses and other assets		$ 9,000

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Total, at cost	$ 362,178	$ 362,178
Accumulated depreciation	(160,010)	(148,140)
Total, net	202,168	214,038
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	198,015	198,015
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	128,849	128,849
R And D Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	25,184	25,184
Furniture [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	$ 10,130	$ 10,130

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 11,870	$ 6,489

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,846,967	$ 3,840,903
Trademarks	26,142	26,142
Total at cost	3,873,109	3,867,045
Accumulated Amortization	(3,840,842)	(3,839,113)
Total net	$ 32,267	$ 27,932

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,729	$ 45,316
Intangible impairment expense		$ 3,606

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Payables and Accruals [Abstract]
Accounts payable	$ 905,736	$ 741,111
Accrued payroll and related taxes	243,304	221,774
Total	$ 1,149,040	$ 962,885

RELATED PARTY NOTES PAYABLE (De

RELATED PARTY NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2021	Jun. 30, 2021
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Notes payable and accrued interest	$ 44,554	$ 48,267
Debt instrument maturity date		Jun. 30, 2022
Annual monthly payments		$ 3,100
Debt term		24 months
Four Directors [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Notes payable and accrued interest	$ 20,000	$ 20,300
Debt interest rate	6.00%
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Proceeds from related party debt		$ 3,500,000

NOTES PAYABLE AND CONVERTIBLE_2

NOTES PAYABLE AND CONVERTIBLE NOTES (Details Narrative) - USD ($)	Jun. 15, 2020	May 02, 2020	Apr. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	May 01, 2022	Mar. 31, 2021	Jan. 31, 2020
Short-term Debt [Line Items]
Notes payable									$ 42,500
Debt instrument, interest rate									6.00%
Convertible Notes payable				$ 37,860				$ 39,528
Convertible notes maturity date				Jun. 30, 2022
Debt instrument, periodic monthly payment				$ 3,100
Debt conversion, amount			$ 230,000
Debt conversion, shares issued			80,522
Conversion price per share	$ 0.28		$ 2.89	$ 0.28
Accrued interest			$ 2,658
Discount on debt	$ 206,000
RedDiamond Partners, LLC [Member]
Short-term Debt [Line Items]
Unamortized debt discount				$ 333,333				0
Convertible Note Payable [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate			10.00%
Convertible Notes payable								235,671
Debt principal amount								230,000
Accrued interest, current								5,671
Debt conversion, amount			$ 2,658
Debt conversion, shares issued			80,522
Conversion price per share			$ 2.89
Payment for interest				3,093	$ 3,397
Convertible Notes Payable [Member] | Derivative [Member]
Short-term Debt [Line Items]
Discount on debt				206,000
Convertible Notes Payable [Member] | Investor [Member]
Short-term Debt [Line Items]
Discount on debt				2,500
Legal fees				2,500
Convertible Notes Payable [Member] | Think Warrants [Member]
Short-term Debt [Line Items]
Fair value of warrants				31,500
Payment of convertible debt				$ 61,500
Number of warrants issued				75,000
Convertible Notes Payable [Member] | Think Equity [Member]
Short-term Debt [Line Items]
Fair value of warrants				$ 52,399
Convertible Notes Payable [Member] | RedDiamond Partners, LLC [Member]
Short-term Debt [Line Items]
Notes payable				$ 354,779
Debt instrument, interest rate				12.50%
Debt principal amount				$ 352,941
Shares issued, price per share				$ 0.28
Unamortized debt discount				$ 52,941
Original issue discount percentage				15.00%
Accrued interest				$ 1,838
Number of warrants purchase				557,143
Fair value of warrants				$ 91,500
Reduction of various discounts on debt						$ 0
Interest expenses				19,608
Payment of convertible debt				30,000
Convertible Notes Payable [Member] | RedDiamond Partners, LLC [Member] | Warrant [Member]
Short-term Debt [Line Items]
Discount on debt				91,500
Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Notes payable				$ 7,436				$ 39,020
Debt instrument, interest rate		1.00%
Debt principal amount		$ 38,665
Convertible notes maturity date		May 1, 2022
Forgiveness of debt		$ 31,680
Paycheck Protection Program [Member] | Forecast [Member]
Short-term Debt [Line Items]
Debt instrument, periodic monthly payment							$ 738

SHARE-SETTLED DEBT OBLIGATION_2

SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY (Details Narrative) - USD ($)	Sep. 02, 2020	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Oct. 15, 2020	Jan. 31, 2020
Schedule of Capitalization, Long-term Debt [Line Items]
Accrued Interest			$ 2,658
Notes payable						$ 42,500
Debt interest rate						6.00%
Annual monthly payments		$ 3,100
Debt instrument maturity date		Jun. 30, 2022
Share-Settled Debt Obligations [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Notes payable		$ 196,000		$ 196,000
Amended Promissory Note [Member] | David B Masters [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount	$ 59,642
Accrued Interest	6,058
Notes payable	$ 65,700
Debt interest rate	8.00%
Debt default interest rate	20.00%
Conditions of promissory notes, description	The Amendment to Promissory Note requires monthly payments of $3,100 and a maturity date of June 30, 2022, provided however that if the Company shall achieve $1,500,000 in equity sales or achieve gross product sales of $1,500,000, the Company must pay the outstanding balance at that time.
Annual monthly payments	$ 3,100
Debt instrument maturity date	Jun. 30, 2022
Promissory Note [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount		0
Accrued Interest		0
Promissory Note [Member] | David B Masters [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount	$ 195,000				$ 192,500
Accrued Interest					658
Notes payable					193,158
Debt interest rate	3.00%
Conditions of promissory notes, description	David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3% per annum, has a maturity date of August 31, 2022, and required payments of $4,000 per month beginning when the Company’s sale of products reach $3,500,000. The reclassification of the $195,000 was treated as a debt modification.
Annual monthly payments	$ 4,000
Debt instrument maturity date	Aug. 31, 2022
Promissory Note [Member] | David B Masters [Member] | Conversion Agreement [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount					192,500
Accrued Interest					658
Notes payable					196,000
Unamortized discount on debt					3,500
Conversion fee					$ 3,500
Amendment to Promissory Note [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt principal amount		48,267
Accrued Interest		$ 44,554

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS (Details)	Jun. 30, 2020	Jun. 15, 2020$ / shares	Jun. 30, 2021$ / shares	Apr. 30, 2021$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price on valuation date		$ 0.42	$ 0.44
Conversion price		$ 0.28	$ 0.28	$ 2.89
Days to maturity	258 days	273 days
Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, percentage		367	367
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, percentage		0.18	0.18

DERIVATIVE LIABILITY AND EXPE_3

DERIVATIVE LIABILITY AND EXPENSE (Details Narrative) - USD ($)	Jun. 15, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 15, 2021
Derivative Liability And Expense
Recognition of derivative liability	$ 526,800
Discount on debt	206,000
Convertible note embedded derivative liability	0
Derivative expense	$ 320,800		$ 342,200
Corresponding offset to derivative liability				$ 526,800
Derivative liability		0	0
Derivative expense		$ 0	$ 21,400

ACCRUED EXPENSES _ RELATED PA_2

ACCRUED EXPENSES – RELATED PARTY (Details Narrative) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Accounts payable	$ 905,736	$ 741,111
Accrued salaries and payroll taxes payable	243,304	221,774
Related Party [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Accrued expenses, related party	50,898	36,808
Accounts payable	29,855	28,965
Accrued salaries and payroll taxes payable	$ 21,043	$ 7,843

SCHEDULE OF ANNUAL UNDISCOUNTED

SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY (Details) - USD ($)	Jun. 30, 2021	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
2022	$ 20,020
2023	27,167
2024	27,710
2025	28,265
2026	28,830
2027	19,474
Total	151,466
Less: amount representing interest	(276)
Total	$ 151,190	$ 189,600

SCHEDULE OF BASE RENT LEASE PAY

SCHEDULE OF BASE RENT LEASE PAYMENTS (Details) - USD ($)	Jun. 30, 2021	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 151,190
Base rent payments included in prepaid expenses
Present value of future base rent lease payments – net	$ 151,190	$ 189,600

SCHEDULE OF LEASE CURRENT AND N

SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 151,190
Total operating lease assets	151,190	$ 157,760	$ 189,600
Operating lease current liability	26,754	26,582
Operating lease other liability	124,436	$ 131,178
Operating lease liability	$ 151,190		$ 189,600

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	May 03, 2017ft²	Jan. 31, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2021USD ($)
Entity Listings [Line Items]
Area of land | ft²	3,577
Annual increase in base rent, percentage	0.02
Lease term description	This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days.	In January 2020, the Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026
Notes Payable		$ 42,500
Accrued expenses		7,500
Base rent			$ 2,205		$ 2,205
Rent expense			$ 11,511	$ 13,568
Operating lease treasury rate			0.12%
Operating lease right-of-use		189,600	$ 151,190		157,760
Operating lease liability		$ 189,600	$ 151,190
Weighted average remaining lease term			6 years
Weighted average discount rate			0.12%
Operating lease payment			$ 151,466
Gel-Del Technologies, Inc. [Member]
Entity Listings [Line Items]
Operating lease payment			$ 330,000		$ 330,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 490,629	$ 814,008
Net cash used in operating activities	255,861	235,331
Accumulated deficit	58,602,055		$ 58,111,426
Working capital	1,094,921
Stockholders' deficit	$ 716,178	$ 1,575,434	$ 896,979	$ 1,036,170

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding, Ending Balance	1,081,668	1,234,295
Weighted-Average Exercise Price, Outstanding, Ending Balance	$ 2.02	$ 2.12
Warrants Exercisable, Outstanding, Ending Balance	881,982	1,027,092
Weighted-Average Exercisable Price, Outstanding, Ending Balance	$ 2	$ 2.13
Number of Warrants, Issued in conjunction with convertible debt		158,036
Weighted-Average Exercise Price, Issued in conjunction with convertible debt		$ 1.40
Number of Warrants, Sold		10,000
Weighted-Average Exercise Price, Sold for cash		$ 4
Number of Warrants, Granted		72,596
Weighted-Average Exercise Price, Issued and granted		$ 1.52
Number of Warrants, Exercised for cash	(4,500)	(205,946)
Weighted-Average Exercise Price, Exercised for cash	$ (8.89)	$ (2.21)
Number of Warrants, Cashless warrant exercises	(237,724)	(142,313)
Weighted-Average Exercise Price, Cashless warrant exercises	$ (1.58)	$ (1.64)
Number of Warrants, Expired		(45,000)
Weighted-Average Exercise Price, Expired		$ (3.78)
Number of Warrants, Cancelled	(108,000)
Weighted-Average Exercise Price, Canceled	$ (1.80)
Number of Warrants, Outstanding, Ending Balance	731,444	1,081,668
Weighted-Average Exercise Price, Outstanding, Ending Balance	$ 2.15	$ 2.02
Warrants Exercisable, Outstanding, Ending Balance	557,069	881,982
Weighted-Average Exercisable Price, Outstanding, Ending Balance	$ 2.17	$ 2

SCHEDULE OF RANGE OF WARRANT PR

SCHEDULE OF RANGE OF WARRANT PRICES (Details) - $ / shares	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	731,444
Weighted-Average Exercise Price, outstanding	$ 2.15	$ 2.02		$ 2.12
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 9 months
Number of Warrants, Exercisable	557,069	881,982		1,027,092
Weighted-Average Exercise Price, Exercisable	$ 2.17	$ 2		$ 2.13
Minimum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	1.20		$ 1.33
Maximum [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	$ 10		$ 17.28
Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	419,831
Range One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-Average Exercise Price, outstanding	$ 1.35
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 8 months 4 days
Number of Warrants, Exercisable	397,331
Weighted-Average Exercise Price, Exercisable	$ 1.35
Range One [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	1.20
Range One [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	$ 2
Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	207,938
Range Two [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-Average Exercise Price, outstanding	$ 2.48
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 1 month 2 days
Number of Warrants, Exercisable	56,063
Weighted-Average Exercise Price, Exercisable	$ 3.15
Range Two [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	2.01
Range Two [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	$ 4
Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	103,675
Range Three [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-Average Exercise Price, outstanding	$ 4.77
Weighted-Average Remaining Contractual Life (Years), Outstanding	1 year 3 months 25 days
Number of Warrants, Exercisable	103,675
Weighted-Average Exercise Price, Exercisable	$ 4.77
Range Three [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	4.01
Range Three [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of Warrant Exercise Price	$ 10

COMMON STOCK AND WARRANTS (Deta

COMMON STOCK AND WARRANTS (Details Narrative)	Jul. 10, 2020shares	Jun. 15, 2020USD ($)$ / sharesshares	Jun. 30, 2021$ / sharesshares	May 31, 2021$ / sharesshares	Apr. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Jun. 30, 2020USD ($)$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued										50,000
Conversion of shares					80,522
Conversion of notes | $					$ 230,000
Accrued interest | $					$ 2,658
Conversion price | $ / shares		$ 0.28	$ 0.28		$ 2.89	$ 0.28	$ 0.28
Proceeds from exercise of warratns | $							$ 40,000
Value of shaes issued for compensaton | $							55,674	$ 183,244
Value of stock sold | $							343,098
Stock-based compensation | $							55,674	$ 183,244
Expense related to warrants issued and outstanding | $							$ 104,000
Investor And Broker [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares of common stock		158,036
Warrants exercise price | $ / shares		$ 1.40
Warrant to purchase of common stock, value | $		$ 265,500
Warrants exercise term		5 years
Value of warrant vested | $		$ 91,500
Minimum [Member] | Measurement Input, Price Volatility [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant measurement inputs			3.50			3.50	3.50
Minimum [Member] | Measurement Input, Expected Term [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise term			3 years			3 years	3 years
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant measurement inputs			0.0029			0.0029	0.0029
Maximum [Member] | Measurement Input, Price Volatility [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant measurement inputs			4.33			4.33	4.33
Maximum [Member] | Measurement Input, Expected Term [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise term			5 years			5 years	5 years
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant measurement inputs			0.0116			0.0116	0.0116
One Share of Common Stock and 1/2 Warrant Share [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares of common stock									20,000
Warrant to purchase of common stock, value | $									$ 34,709
Fair value of warrants | $									34,709
Warrant transaction cost | $									17,291
Value of stock sold | $									$ 52,000
Video Marketing Services [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shaes issued for compensaton										30,000
Value of shaes issued for compensaton | $										$ 32,453
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued							294,042
Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant granted to purchase shares of common stock								206,873
2020 Plan [Member] | Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Restricted shares granted							34,300
Options vested							300
Warrant Holders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued			43,324	79,767
Warrants to purchase shares of common stock			56,250	139,286	4,500	56,250	56,250
Warrants exercise price | $ / shares			$ 2.22	$ 1.40	$ 4.44	$ 2.22	$ 2.22
Proceeds from exercise of warratns | $					$ 40,000
John Lai's [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued				36,915
Warrants to purchase shares of common stock				42,188
Warrants exercise price | $ / shares				$ 1.33
Accredited Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued						49,014
Warrants exercise price | $ / shares			$ 7			$ 7	$ 7
Stock Issued During Period, Value, New Issues | $						$ 343,098
One Investor [Member] | Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares of common stock								10,000		10,000
Warrants exercise price | $ / shares								$ 4		$ 4
Warrant to purchase of common stock, value | $								$ 17,291		$ 17,291
Warrants exercise term								3 years		3 years
Directors Officers And Consultants [Member] | Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares of common stock								38,837		38,837
Warrant to purchase of common stock, value | $								$ 57,717		$ 57,717
Directors Officers And Consultants [Member] | Warrants [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price | $ / shares								$ 1.40		$ 1.40
Directors Officers And Consultants [Member] | Warrants [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price | $ / shares								1.60		1.60
Directors Officers And Consultants [Member] | Warrants [Member] | Weighted Average [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price | $ / shares								$ 1.52		$ 1.52
2020 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	1,000,000
Expiration date	Jul. 10, 2030
Number of shares reserved for future issuance	1,000,000
2020 Equity Incentive Plan [Member] | Nonemployee Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maximum number of shares per employee	10,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Aug. 13, 2021	Jul. 31, 2021	Jun. 30, 2021
Subsequent Event [Line Items]
Proceeds from sale of stock			$ 343,098
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of stock, shares	2,500,000
Sale of stock price per share	$ 4.50
Subsequent Event [Member] | Underwriter [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	125,000
Warrant exercise price	$ 5.625
Warrants and Rights Outstanding, Maturity Date	Aug. 10, 2026
Subsequent Event [Member] | Over-Allotment Option [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	375,000
Subsequent Event [Member] | Two Investors [Member]
Subsequent Event [Line Items]
Sale of stock, shares		11,000
Sale of stock price per share		$ 7
Proceeds from sale of stock	$ 9,800,000	$ 77,000